Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yung Chyung

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|December 5, 2024
Human Genetic Evidence to Inform Clinical Development of IL-6 Signaling Inhibition for Abdominal Aortic AneurysmStephen Burgess, Héléne T Cronjé, Emil deGoma, et al.
Annals of Emergency Medicine|September 4, 2014
Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trialLawrence M Lewis, Charles Graffeo, Pascal Crosley, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 2, 2014
A phase 1 study investigating DX-2930 in healthy subjectsYung Chyung, Bradley Vince, Ryan Iarrobino, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 23, 2015
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacksTimothy J Craig, H Henry Li, Marc Riedl, et al.
Advances in Therapy|May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular AtrophyDoreen Barrett, Sanela Bilic, Yung Chyung, et al.
Neurology|February 8, 2024
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ StudyThomas O Crawford, Basil T Darras, John W Day, et al.
The New England Journal of Medicine|February 23, 2017
Inhibiting Plasma Kallikrein for Hereditary Angioedema ProphylaxisAleena Banerji, Paula Busse, Mustafa Shennak, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Arteriosclerosis, Thrombosis, and Vascular Biology|December 5, 2024
Human Genetic Evidence to Inform Clinical Development of IL-6 Signaling Inhibition for Abdominal Aortic AneurysmStephen Burgess, Héléne T Cronjé, Emil deGoma, et al.
Annals of Emergency Medicine|September 4, 2014
Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trialLawrence M Lewis, Charles Graffeo, Pascal Crosley, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 2, 2014
A phase 1 study investigating DX-2930 in healthy subjectsYung Chyung, Bradley Vince, Ryan Iarrobino, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 23, 2015
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacksTimothy J Craig, H Henry Li, Marc Riedl, et al.
Advances in Therapy|May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular AtrophyDoreen Barrett, Sanela Bilic, Yung Chyung, et al.
Neurology|February 8, 2024
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ StudyThomas O Crawford, Basil T Darras, John W Day, et al.
The New England Journal of Medicine|February 23, 2017
Inhibiting Plasma Kallikrein for Hereditary Angioedema ProphylaxisAleena Banerji, Paula Busse, Mustafa Shennak, et al.
Pageof 1